enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [6] [7] The medications work in different ways: fluticasone furoate is an inhaled corticosteroid ...

3. A Guide for Living With COPD - AOL

   www.aol.com/guide-living-copd-210000074.html

   Up to 33% of people with COPD have mental-health conditions such as anxiety and depression, according to another review published in 2022.And not only can the condition take a toll on your mood ...

4. Chronic obstructive pulmonary disease - Wikipedia

   en.wikipedia.org/wiki/Chronic_obstructive...

   Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. [8] GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea or shortness of breath, cough, sputum production and/or exacerbations) due to abnormalities of the airways (bronchitis ...

5. Fluticasone furoate/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/vilanterol

   Fluticasone furoate/vilanterol, sold under the brand name Breo Ellipta among others, is a combination medication for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. [3] It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β 2 agonist (ultra-LABA). [3]

6. FDA approves new COPD drug developed by firm in Raleigh ... - AOL

   www.aol.com/news/fda-approves-copd-drug...

   A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade.

7. US FDA approves Verona Pharma's inhaled COPD therapy - AOL

   www.aol.com/news/us-fda-approves-verona-pharmas...

   The U.S. FDA's assent for the therapy, to be sold under the brand Ohtuvayre, is the company's first and provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary disease.